Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen

Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies (2022) Atreya R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, et al. Conference contribution Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study (2022) Bokemeyer B, Plachta-Danielzik S, Di Giuseppe R, Deppe H, Mohl W, Teich N, Hoffstadt M, et al. Conference contribution Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn's Disease and inadequate response to risankizumab maintenance therapy (2022) Baert FJ, Atreya R, Kakuta Y, Long M, Roblin X, Neimark E, Song A, et al. Conference contribution Neutrophils prevent rectal bleeding in Ulcerative Colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis (2022) Leppkes M, Lindemann A, Goesswein S, Paulus S, Roth D, Hartung A, Liebing E, et al. Conference contribution Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study (2022) Di Giuseppe R, Plachta-Danielzik S, Bokemeyer B, Efken P, Mohl W, Hoffstadt M, Krause T, et al. Conference contribution Burden of bowel urgency across specific treatment groups among Ulcerative Colitis patients - real world global study analyses (2022) Atreya R, Redondo I, Hill J, Streit P, Hartz S, Knight H, Barlow S, et al. Conference contribution Non-invasive assessment of intestinal inflammatory activity in Ulcerative Colitis by Multispectral Optoacoustic Tomography (MSOT) (2022) Klett D, Jesper D, Vitali F, Federle A, Atreya R, Strobel D, Leppkes M, et al. Conference contribution Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy? (2022) Atreya R, Bojarski C, Kühl AA, Trajanoski Z, Neurath M, Siegmund B Journal article, Review article Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected (2022) Atreya R, Neurath M Journal article The outcome of patients with inflammatory bowel disease-associated colorectal cancer is not worse than that of patients with sporadic colorectal cancer-a matched-pair analysis of survival (2021) Vitali F, Wein A, Rath T, Eckstein M, Neufert C, Siebler J, Atreya R, et al. Journal article